ArticleBMC medicine2020
The cost-effectiveness of controlling dengue in Indonesia using wMel Wolbachia released at scale: a modelling study.
Article in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue.The New England journal of medicine · 2021Trial
- The cost-effectiveness of Wolbachia-based biocontrol interventions for dengue: A scoping review of the available evidence.PLoS neglected tropical diseases · 2026Article
- Navigating evidence-informed decision making for arboviral disease control in Pacific Island countries.BMC global and public health · 2026Review
- An Ecological Impact Assessment Framework and Integrated Management Pathway for Large-Scale Chemical Mosquito Control in Urban Areas.ACS environmental Au · 2026Article
- Present and Future of Mosquito-Borne Disease Control in Europe with a Specific Focus on the Mediterranean.Insects · 2026Review
- "Basically a PR exercise…": a qualitative study of expert perspectives on 'performative versus evidence-informed' dengue vector control in the Asia-Pacific region.BMJ global health · 2025Article
- Long-Term Durability and Public Health Impact of City-WideTropical medicine and infectious disease · 2025Article
- Review
- Why the growth of arboviral diseases necessitates a new generation of global risk maps and future projections.PLoS computational biology · 2025Article
- ExploitingPathogens (Basel, Switzerland) · 2025Review
- Article
- Assessing the direct and spillover protective effectiveness of Wolbachia-mediated introgression to combat dengue.EBioMedicine · 2024Article
- Review
- Effects of climate change and human activities on vector-borne diseases.Nature reviews. Microbiology · 2024Review
- Simulation-based economic evaluation of the Wolbachia method in Brazil: a cost-effective strategy for dengue control.Lancet regional health. Americas · 2024Article
- Cost-effectiveness of aLancet regional health. Americas · 2024Article
- Successful introgression of wMel Wolbachia into Aedes aegypti populations in Fiji, Vanuatu and Kiribati.PLoS neglected tropical diseases · 2024Article
- Introduction ofiScience · 2024Article
- Occupational exposure to malaria, leishmaniasis and arbovirus vectors in endemic regions: A systematic review.Current research in parasitology & vector-borne diseases · 2024Review
- Estimating dengue disease and economic burden to inform municipal-level policymakers: Method for a pragmatic city-level observational cohort study.Gates open research · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRelease of virus-blocking Wolbachia-infected mosquitoes is an emerging disease control strategy that aims to control dengue and other arboviral infections. Early entomological data and modelling analyses have suggested promising outcomes, and wMel Wolbachia releases are now ongoing or planned in 12 countries. To help inform government, donor, or philanthropist decisions on scale-up beyond single city releases, we assessed this technology's cost-effectiveness under alternative programmatic options.
methodsUsing costing data from existing Wolbachia releases, previous dynamic model-based estimates of Wolbachia effectiveness, and a spatially explicit model of release and surveillance requirements, we predicted the costs and effectiveness of the ongoing programme in Yogyakarta City and three new hypothetical programmes in Yogyakarta Special Autonomous Region, Jakarta, and Bali.
resultsWe predicted Wolbachia to be a highly cost-effective intervention when deployed in high-density urban areas with gross cost-effectiveness below $1500 per DALY averted. When offsets from the health system and societal perspective were included, such programmes even became cost saving over 10-year time horizons with favourable benefit-cost ratios of 1.35 to 3.40. Sequencing Wolbachia releases over 10 years could reduce programme costs by approximately 38% compared to simultaneous releases everywhere, but also delays the benefits. Even if unexpected challenges occurred during deployment, such as emergence of resistance in the medium-term or low effective coverage, Wolbachia would remain a cost-saving intervention.
conclusionsWolbachia releases in high-density urban areas are expected to be highly cost-effective and could potentially be the first cost-saving intervention for dengue. Sites with strong public health infrastructure, fiscal capacity, and community support should be prioritised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.